查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735639

全球原代細胞培養市場規模（依產品、應用、細胞類型、區域範圍、預測）

Global Primary Cell Culture Market Size By Product (Primary Cell, Reagents And Supplements, Media), By Application (Vaccine Production, Stem Cell Therapy, Cancer Research), By Cell Type (Animal Cells, Human Cells), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

原代細胞培養市場規模及預測

2024 年原代細胞培養市場規模價值 45.3 億美元，預計 2032 年將達到 107.1 億美元，2026 年至 2032 年的複合年成長率為 11.37%。

  • 原代細胞培養是直接從組織分離細胞並在受控的實驗室條件下培養細胞的過程。
  • 原代細胞培養在研究和開發中變得越來越重要，因為它們可以緊密模擬生物體細胞的生理行為，提供更準確的研究模型。
  • 在這種方法中，通常會從生物體中取出細胞並進行培養，而不會對其自然狀態進行顯著改變，從而確保保留重要的生物學特性。
  • 原代細胞培養在藥物發現、毒理學、癌症研究和再生醫學等領域的發展日益增多，它們被用於研究細胞行為、測試治療劑和開發個人化治療。
  • 對更準確、更可靠的體外模型的需求不斷成長，進一步推動了原代細胞的使用，因為與連續細胞株相比，原代細胞更接近體內條件。
  • 培養中的原代細胞的生長需要特定的生長因子和營養物質的存在，這些生長因子和營養物質需要經過精心調節才能維持細胞活力和功能。
  • 生長因子，例如細胞激素和激素，對於促進這些培養物中的細胞增殖、分化和存活至關重要。

原代細胞培養的全球市場動態

影響全球原代細胞培養市場的關鍵市場動態是：

關鍵促進因素

  • 個人化醫療需求不斷成長：人們對個人化和精準醫療的興趣日益成長，預計將推動原代細胞培養市場的發展，因為這些細胞對於開發針對特定患者的治療方法至關重要。預計該市場將受益於對需要精確試管內模型的先進醫療療法的投資不斷增加。根據個人化醫療聯盟的數據，預計在2017年至2022年期間，正在開發的個人化藥物數量將增加34%，達到286治療方法以上。
  • 專注於藥物發現和開發：對藥物發現的日益重視預計將加速原代細胞培養的應用，尤其是在療效和毒性測試方面。這些細胞將透過提供更可靠的人體細胞模型，在減少對動物試驗的依賴方面發揮關鍵作用。
  • 癌症研究投資：癌症研究投資龐大，培養細胞被廣泛用於研究癌細胞的行為，預計將推動原代細胞培養市場的發展。全球癌症發生率的上升預計將刺激對先進細胞模型的需求，從而促進市場成長。
  • 3D細胞培養的應用不斷擴大：3D細胞培養預計將提升原代細胞在研究中的相關性，因為它比傳統的2D培養更能有效模擬體內環境。這一趨勢可望擴大原代細胞培養在各研究領域的應用範圍。根據VMR預測，2022年3D細胞培養市場規模將達到18.8億美元，到2030年將達到43億美元，2023年至2030年的複合年成長率為10.87%。

主要挑戰

  • 原代細胞培養高成本：原代細胞培養過程的高成本，尤其是在研究資金有限的地區，預計將抑制市場成長。採購原代細胞和維持特定生長條件的費用預計將對市場擴張構成關鍵挑戰。
  • 技術的複雜性和多變性：原代細胞培養的技術複雜性和固有的多變性可能會阻礙其廣泛應用，並限制大規模研究和工業應用的可擴展性和可重複性。
  • 原代細胞供應有限：由於用於培養的人體和動物組織的採購仍然具有挑戰性，高品質原代細胞供應有限預計將阻礙市場成長。圍繞組織採購的倫理問題和監管限制預計將進一步限制供應鏈。
  • 污染風險和壽命短：與永生化細胞株相比，原代細胞的污染風險更高，壽命更短，這可能會限制市場發展。這些限制預計會增加實驗室操作的挑戰，並降低長期研究的效率。

主要趨勢

  • 聚焦幹細胞研究：再生醫學對高品質原代細胞的需求正推動幹細胞研究日益受到重視，預計這將對原代細胞培養市場產生重大影響。這一趨勢可望推動生物技術和製藥業的研發投資。
  • 產學合作：學術機構與生物製藥公司之間日益成長的夥伴關係預計將推動原代細胞培養市場的發展。此類合作可望促進創新，並加速新型細胞治療方法和研究工具的商業化。
  • 對先進組織工程的需求：對先進組織工程解決方案的旺盛需求預計將推動原代細胞培養在研究和臨床應用中的應用。這一趨勢將為類器官和生物工程組織的開發開闢新的途徑，進一步擴大市場潛力。

目錄

第1章 全球原代細胞培養市場簡介

  • 市場介紹
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球原代細胞培養市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章 全球原代細胞培養市場（依產品分類）

  • 概述
  • 原代細胞
  • 試劑和補充劑
  • 細胞培養基

第6章 全球原代細胞培養市場（依應用）

  • 概述
  • 疫苗生產
  • 幹細胞治療
  • 癌症研究
  • 其他

7. 全球原代細胞培養市場（依細胞類型）

  • 概述
  • 動物細胞
  • 人類細胞

第8章全球原代細胞培養市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

第9章全球原代細胞培養市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第10章 公司簡介

  • Thermo Fisher Scientific Inc.
  • Lonza
  • Merck KGaA
  • Axol Bioscience Ltd
  • GE Healthcare
  • STEMCELL Technologies Inc
  • Cell Biologics
  • ZenBio
  • ScienCell Research Laboratories
  • PPA Research Group

第11章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第12章 附錄

  • 相關調查
簡介目錄
Product Code: 35782

Primary Cell Culture Market Size And Forecast

Primary Cell Culture Market size was valued at USD 4.53 Billion in 2024 and is projected to reach USD 10.71 Billion by 2032, growing at a CAGR of 11.37% from 2026 to 2032.

  • Primary cell culture is the process by which cells are isolated directly from tissues and grown under controlled laboratory conditions.
  • The growing importance of primary cell culture in research and development is attributed to its ability to closely mimic the physiological behavior of cells within an organism, providing more accurate study models.
  • In this method, cells are typically harvested from a living organism and cultured without significant alterations to their natural state, ensuring the retention of critical biological characteristics.
  • Applications of primary cell cultures are rising in fields such as drug discovery, toxicology, cancer research, and regenerative medicine, where they are used to study cell behavior, test therapeutic agents, and develop personalized treatments.
  • The increasing demand for more precise and reliable in vitro models has further driven the use of primary cells, given their closer resemblance to in vivo conditions compared to continuous cell lines.
  • The growth of primary cells in culture requires the presence of specific growth factors and nutrients, which are carefully regulated to maintain cellular viability and function.
  • Growth factors, such as cytokines and hormones, are essential for promoting cell proliferation, differentiation, and survival in these cultures.

Global Primary Cell Culture Market Dynamics

The key market dynamics that are shaping the global primary cell culture market include:

Key Drivers:

  • Growing Demand for Personalized Medicine: The rising interest in personalized and precision medicine is anticipated to drive the primary cell culture market, as these cells are integral to developing patient-specific therapies. The market is expected to benefit from increasing investments in advanced medical treatments that require accurate in vitro models. According to the Personalized Medicine Coalition, the number of personalized medicines in development increased by 34% between 2017 and 2022, reaching over 286 therapies.
  • Focus on Drug Discovery and Development: The increasing focus on drug discovery is projected to accelerate the adoption of primary cell cultures, especially for testing efficacy and toxicity. These cells are likely to play a critical role in reducing reliance on animal testing by offering more reliable human-based cell models.
  • Investments in Cancer Research: High investments in oncology research are expected to fuel the primary cell culture market, with these cultures being widely used in studying cancer cell behavior. Rising cancer incidence globally is anticipated to boost demand for advanced cellular models, increasing market growth.
  • Growing Use of 3D Cell Cultures: The adoption of 3D cell cultures in research is estimated to enhance the relevance of primary cells, given their ability to replicate in vivo environments more effectively than traditional 2D cultures. This trend is expected to expand the application range of primary cell cultures in various research domains. According to VMR, 3D Cell Culture Market size was valued at USD 1.88 Billion in 2022 and is projected to reach USD 4.30 Billion in 2030, at a CAGR of 10.87% from 2023 to 2030.

Key Challenges:

  • High Costs of Primary Cell Cultures: The high costs associated with primary cell culture processes are anticipated to restrain market growth, particularly in regions with limited research funding. The expense of procuring primary cells and maintaining specific growth conditions is expected to be a key challenge for market expansion.
  • Technical Complexity and Variability: The technical complexity and inherent variability of primary cell cultures are likely to impede widespread adoption. This challenge is projected to limit scalability and reproducibility in large-scale research and industrial applications.
  • Limited Availability of Primary Cells: The limited availability of high-quality primary cells is expected to hamper market growth, as sourcing human or animal tissues for these cultures remains difficult. Ethical concerns and regulatory restrictions around tissue procurement are anticipated to further restrain supply chains.
  • Contamination Risks and Shorter lifespan: The higher risk of contamination and the shorter lifespan of primary cells compared to immortalized cell lines are likely to restrain the market. These limitations are expected to increase operational challenges for laboratories, reducing the efficiency of long-term studies.

Key Trends:

  • Focus on Stem Cell Research: The rising emphasis on stem cell research is expected to significantly influence the primary cell culture market, given the need for high-quality primary cells in regenerative medicine. This trend is likely to enhance investment in research and development across the biotechnology and pharmaceutical sectors.
  • Collaboration between Academia and Industry: Growing partnerships between academic institutions and biopharmaceutical companies are projected to boost the primary cell culture market. These collaborations are anticipated to drive innovation and expedite the commercialization of new cell-based therapies and research tools.
  • Demand for Advanced Tissue Engineering: The high demand for advanced tissue engineering solutions is expected to drive the adoption of primary cell cultures in research and clinical applications. This trend is likely to open new avenues for developing organoids and bioengineered tissues, further expanding market potential.

Global Primary Cell Culture Market Regional Analysis

Here is a more detailed regional analysis of the global primary cell culture market:

North America:

  • According to Verified Research Market Analyst, North America is anticipated to dominate the primary cell culture market due to the presence of advanced biotechnology and pharmaceutical industries.
  • The United States is projected to lead the regional market, driven by increasing investments in research and development, as well as the growing focus on personalized medicine and drug discovery.
  • A well-established healthcare infrastructure and strong academic-industry collaborations are expected to further support market growth in this region.
  • The rising prevalence of chronic diseases such as cancer is also likely to drive demand for primary cell cultures in North American research institutions. The American Cancer Society estimates that there will be 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2024.

Asia Pacific:

  • The Asia Pacific region is estimated to experience the fastest growth in the primary cell culture market, driven by the rising investment in biotechnology and pharmaceutical sectors in countries such as China, Japan, and India.
  • According to VMR, Biotechnology Market size was valued at USD 1023.92 Billion in 2023 and is projected to reach USD 2590.03 Billion by 2032, growing at a CAGR of 12.3% from 2026 to 2032.
  • The increasing government initiatives to promote life sciences research, along with the expanding clinical research activities, are projected to propel market growth in the region.
  • China's growing biotechnology industry, combined with its focus on innovation and healthcare, is anticipated to significantly boost the market for primary cell cultures.
  • India is also likely to witness rapid growth, driven by a rising number of pharmaceutical companies and a growing focus on drug development and testing.

Global Primary Cell Culture Market: Segmentation Analysis

The Global Primary Cell Culture Market is Segmented on the basis of Product, Application, Cell Type, And Geography.

Primary Cell Culture Market, By Product

  • Primary Cell
  • Reagents And Supplements
  • Media

Based on Product, the market is bifurcated into Primary Cell, Reagents And Supplements, and Media. The media segment is anticipated to hold the largest share of the primary cell culture market due to its critical role in supporting cell growth, proliferation, and differentiation. Media is projected to experience sustained demand as it is essential for maintaining the viability and functionality of primary cells throughout research and production processes.

Primary Cell Culture Market, By Application

  • Vaccine Production
  • Stem Cell Therapy
  • Cancer Research

Based on Application, the Global Primary Cell Culture Market is divided into Vaccine Production, Stem Cell Therapy, and Cancer Research. The vaccine production segment is projected to hold the largest share of the primary cell culture market. The increasing use of primary cells in the development and production of vaccines is anticipated to drive this growth. Primary cells are widely used due to their ability to mimic natural human cell environments, which is crucial for creating vaccines that are safe and effective.

Primary Cell Culture Market, By Cell Type

  • Animal Cells
  • Human Cells

Based on Cell Type, the market is segmented into Animal Cells and Human Cells. Human cells are anticipated to hold the largest share of the primary cell culture market, driven by their increasing application in drug discovery, personalized medicine, and cancer research. The demand for human primary cells is projected to rise due to their ability to provide more accurate and clinically relevant models for studying human physiology and disease.

Primary Cell Culture Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Geography, the global primary cell culture market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest share of the primary cell culture market, driven by its advanced biotechnology and pharmaceutical industries. The region is projected to maintain its dominance due to the increasing focus on personalized medicine and rising investments in drug discovery and development.

Key Players

The "Global Primary Cell Culture Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Merck KGaA, Lonza, Corning Incorporated, Danaher Corporation, GE Healthcare, PromoCell GmbH, American Type Culture Collection, FUJIFILM Irvine Scientific, MatTek Ltd, Axol Bioscience Ltd, STEMCELL Technologies Inc, Cell Biologics, ZenBio, ScienCell Research Laboratories, and PPA Research Group. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Latest Developments

  • In March 2024, Lonza announced a collaboration with a renowned biopharmaceutical company to develop a new cell culture medium tailored exclusively for breakthrough cell therapy.
  • In February 2024, Thermo Fisher Scientific introduced a new line of cryopreserved primary human hepatocytes, seeking to give researchers with a more consistent and trustworthy source of these cells for drug discovery applications.
  • In February 2024, Corning Incorporated expanded its portfolio of Transwell(R) co-culture devices, which are intended to increase the efficiency and accuracy of cell-based assays used in drug development.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRIMARY CELL CULTURE MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PRIMARY CELL CULTURE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PRIMARY CELL CULTURE MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Primary Cell
  • 5.3 Reagents And Supplements
  • 5.4 Media

6 GLOBAL PRIMARY CELL CULTURE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Vaccine Production
  • 6.3 Stem Cell Therapy
  • 6.4 Cancer Research
  • 6.5 Others

7 GLOBAL PRIMARY CELL CULTURE MARKET, BY CELL TYPE

  • 7.1 Overview
  • 7.2 Animal Cells
  • 7.3 Human Cells

8 GLOBAL PRIMARY CELL CULTURE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL PRIMARY CELL CULTURE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Thermo Fisher Scientific Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Lonza
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Merck KGaA
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Axol Bioscience Ltd
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 GE Healthcare
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 STEMCELL Technologies Inc
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Cell Biologics
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 ZenBio
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 ScienCell Research Laboratories
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 PPA Research Group
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research